Non US Residents | Contact Us | Site Map | Large Text VersionRegular Text Version

Welcome to Novartis Oncology US - This site is intended for US Residents only

 

 

 

Products in Development

Research

Product Pipeline

 

Targeting multiple tumor types

The Novartis Oncology pipeline includes compounds in all phases of development, starting with preclinical studies in tumor cell line and animal models through large Phase III randomized trials.

A Pipeline That Spans All Phases

Click on the compound name below to learn more. 

Product Pipeline


All compounds are investigational. Efficacy and safety have not been established. There is no guarantee that they will become commercially available.
*HCD122 is being codeveloped by Novartis Oncology and XOMA.
†Gimatecan is licensed from sigma-tau S.p.A.
†ASA404 (formerly known as AS1404) is licensed from Antisoma, UK.

About Novartis Oncology

We are one of the premier companies providing you with the best oncology treatments available.

mTOR Pathway

Learn more about Novartis Oncology advances in mTOR Pathway.

CAREERS

Careers at Novartis

We are committed to building the smartest and most capable team in the industry.

PRODUCTS

Innovative therapies and practical solutions that change the way patients live with cancer.